Nielsen combines tools for new health offering

Share this article:
When separate data streams are combined, the whole is greater than the sum of its parts. That's the principle Nielsen Health is banking on.

By integrating several of Nielsen's most well-known analytical tools—such as PERQ-HCI, Nielsen Media Research, Nielsen//NetRatings and Nielsen BuzzMetrics—NielsenHealth hopes it can more effectively tackle some of a pharmaceutical marketer's biggest challenges.

“NielsenHealth can make a significant difference by taking a lot of the capabilities and data it has and just repurposing it,” said Matthew Dumas, NielsenHealth managing director.

Health is but one vertical included in a suite of services that the parent company is calling NielsenConnect.

Consider Health's media-tracking and targeting capability. Dumas, who spent nearly a decade working with Procter & Gamble, said he sees “tremendous waste” in evaluating media based on demographics alone.

A more efficient way involves linking Nielsen Media Research's TV and Internet audience measurement data with other panel information to first identify only those suffering from a condition in terms of their media consumption. Then allow a marketer to drill down further.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...